NCT05731804 - Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir | Biotech Hunter

Enrollment

72

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

December 1, 2023

Study Completion Date

December 31, 2023

Conditions

Renal ImpairmentHepatic Impairment

Interventions

DRUG

SIM0417 600 mg; Ritonavir100 mg

SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.

DRUG

SIM0417 375 mg; Ritonavir100 mg

SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.

DRUG

SIM0417 750 mg; Ritonavir100 mg

SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.

Trial Locations (1)

250014

Shandong Provincial Qianfoshan Hospital, Jinan